RE:RE:RE:Turning to Goblet GOBLET - On March 31, 2022. ONCY announced successful completion of the three-patient safety run-in for the third-line mCRC cohort of GOBLET. The first-line mCRC and anal cohorts did not require safety run-ins. I have 2 questions if anyone would care to answer.
1. Would Roche know the up to date status of GOBLET? Presumably Roche knows all about this trial with the fist around it?
2. Was the CAR T abstract released at the same time as BRACELET-1?
As Noteable as pointed out many times, pela appears to be versatile. I think an interested pharma would be gauging immunotherapies that we have not even thought of. For example Roche and anti-TIGIT.
We wait. Cheers.